Skip to main navigation
Skip to search
Skip to main content
Sort by:
Keyphrases
Irritable Bowel Syndrome
100%
Diarrhea-predominant Irritable Bowel Syndrome
100%
Abdominal Pain
100%
Short-chain Fatty Acids
70%
Butyrate
53%
Pain Management
50%
Glucagon-like peptide-1 (GLP-1)
50%
Herbal Medicine
50%
Randomized Clinical Trial
50%
Commensal Bacteria
50%
Gut Microbiota
40%
Diarrhea Patients
30%
Therapeutic Potential
20%
Visceral Hypersensitivity
16%
Pain Symptoms
16%
Fecal Microbiota Transplantation
16%
Mouse Model
13%
Fecal Short-chain Fatty Acids
10%
Fatty Acid Composition
10%
Treatment Challenges
10%
Clinical Trials
10%
Biological Experiment
10%
Transplant Experiment
10%
Butyrate Producer
10%
Randomized Placebo-controlled Trial
10%
Microbial Profile
10%
Gut Microbial Community
10%
Translational Approach
10%
Alleviation
10%
Therapeutic Effect
10%
Clinical Safety
10%
Pathophysiological Mechanisms
10%
Microbiota
10%
Eubacterium Rectale
10%
Gastrointestinal Diseases
10%
Clinical Efficacy
10%
Gut Microbiota Modulation
10%
GLP-1 Signalling
6%
Gut Metabolites
6%
Signaling Axis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Diarrhea
100%
Irritable Colon
100%
Abdominal Pain
100%
Short Chain Fatty Acid
66%
Butyrate
53%
Glucagon-Like Peptide-1
50%
Randomized Clinical Trial
50%
Intestine Flora
45%
Erethism
16%
Feces microflora
15%
Mouse Model
11%
Placebo
8%
Microflora
8%
Gastrointestinal Disease
8%
Eubacterium rectale
8%
Clinical Trial
8%
Therapeutic Effect
8%
Medicine and Dentistry
Short Chain Fatty Acid
50%
Abdominal Pain
50%
Irritable Bowel Syndrome
50%
Diarrhea
50%
Glucagon Like Peptide 1
50%
Analgesia
50%
Gut Microbiota
20%
Hypersensitivity
16%
Gut
10%
Pain (Symptom)
6%
Metabolite
6%